Ikena Oncology Statistics
Total Valuation
Ikena Oncology has a market cap or net worth of $58.39 million. The enterprise value is -$58.47 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ikena Oncology has 48.26 million shares outstanding. The number of shares has increased by 15.63% in one year.
| Current Share Class | 41.89M |
| Shares Outstanding | 48.26M |
| Shares Change (YoY) | +15.63% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 19.47% |
| Float | 7.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.80, with a Debt / Equity ratio of 0.06.
| Current Ratio | 11.80 |
| Quick Ratio | 11.54 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -33.30% and return on invested capital (ROIC) is -21.72%.
| Return on Equity (ROE) | -33.30% |
| Return on Assets (ROA) | -20.44% |
| Return on Invested Capital (ROIC) | -21.72% |
| Return on Capital Employed (ROCE) | -41.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.92M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Ikena Oncology has paid $152,000 in taxes.
| Income Tax | 152,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.37% in the last 52 weeks. The beta is 0.48, so Ikena Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -10.37% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 50.13 |
| Average Volume (20 Days) | 86,491 |
Short Selling Information
The latest short interest is 113,927, so 0.24% of the outstanding shares have been sold short.
| Short Interest | 113,927 |
| Short Previous Month | 151,688 |
| Short % of Shares Out | 0.24% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 1.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | -30.88M |
| Operating Income | -54.55M |
| Pretax Income | -66.78M |
| Net Income | -49.23M |
| EBITDA | -54.06M |
| EBIT | -54.55M |
| Earnings Per Share (EPS) | -$1.02 |
Full Income StatementBalance Sheet
The company has $124.39 million in cash and $7.52 million in debt, giving a net cash position of $116.87 million or $2.42 per share.
| Cash & Cash Equivalents | 124.39M |
| Total Debt | 7.52M |
| Net Cash | 116.87M |
| Net Cash Per Share | $2.42 |
| Equity (Book Value) | 125.93M |
| Book Value Per Share | 2.61 |
| Working Capital | 116.39M |
Full Balance SheetCash Flow
| Operating Cash Flow | -46.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | -46.00M |
| FCF Per Share | -$0.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |